WaveMan
WaveMan · Company
ZIVO · Zivo Bioscience, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ZIVO Zivo Bioscience (ZIVO) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001101026
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter

Zivo Bioscience insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Zivo Bioscience, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
STROME INVESTMENT MANAGEMENT LP
BUY
2026-04-24 SECtraded 2026-04-17
100,000
$200.0K
+349.6%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Oct 13, 2025.
  • The trade is 17.5% of the 572,942 shares held after it.
  • No other insider bought within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider STROME INVESTMENT MANAGEMENT LP bought about $200.0K of ZIVO on Apr 17, 2026.
YALDOO LAITH L
Director
BUY
2026-03-03 SECtraded 2026-02-27
1,543
$15.0K
-32.4%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (9 buys), the last on Feb 10, 2026.
  • -30.5% median (-34.9% mean) 90-day return after 8 previous buys.
  • The trade is 0.3% of the 583,615 shares held after it.
  • 1 other insider bought within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Director YALDOO LAITH L bought about $15.0K of ZIVO on Feb 27, 2026; 1 other insider bought within 30 days.
STROME GROUP, INC.
BUY
2026-02-17 SECtraded 2026-02-12
20,000
$195.4K
-37.5%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jun 2, 2021.
  • The trade is 4.2% of the 472,942 shares held after it.
  • 4 other insiders bought within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider STROME GROUP, INC. bought about $195.4K of ZIVO on Feb 12, 2026; 4 other insiders bought within 30 days.
YALDOO LAITH L
Director
BUY
2026-02-12 SECtraded 2026-02-10
2,434
$25.0K
-37.5%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (8 buys), the last on Jan 14, 2026.
  • -29.5% median (-30.9% mean) 90-day return after 7 previous buys.
  • The trade is 0.4% of the 582,072 shares held after it.
  • 4 other insiders bought within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Director YALDOO LAITH L bought about $25.0K of ZIVO on Feb 10, 2026; 4 other insiders bought within 30 days.
Cornell Alison A
Director
BUY
2026-01-28 SECtraded 2026-01-26
11,709
$100.0K
-40.4%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Aug 22, 2024.
  • +147.2% median (+190.5% mean) 90-day return after 3 previous buys.
  • The trade is 4.2% of the 279,481 shares held after it.
  • 4 other insiders bought within 30 days.
  • No fund added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Cornell Alison A bought about $100.0K of ZIVO on Jan 26, 2026; 4 other insiders bought within 30 days.
40 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 35 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+468.6% year over year
more than 93% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
0.5% of the float short (float per yahoo 2026-10-26) · 7.0 days to cover · settled 2026-09-30
below 86% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ZIVO

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-53.1%12M
-91%-52%-12%+28%2025-102025-122026-022026-042026-062026-082026-10 2026-04-17 · STROME INVESTMENT MANAGEMENT LP bought $200.0K2026-02-12 · STROME GROUP, INC. bought $195.4K2026-01-26 · Cornell Alison A bought $100.0K2026-01-26 · PAYNE JOHN BERNARD bought $100.0K2026-02-10 · YALDOO LAITH L bought $25.0K2025-11-28 · YALDOO LAITH L bought $25.0K2026-02-27 · YALDOO LAITH L bought $15.0K2026-01-14 · Maggiore Christopher D. bought $15.0K2026-01-14 · YALDOO LAITH L bought $15.0K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ZIVO: institutional holders (13F)

13F holdings, latest reported quarter
CoreCap Advisors, LLC
4,360 sh
$17.6K

Congress trades in ZIVO

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ZIVO planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ZIVO financials

Revenue growth
+468.6%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$209.0K
four quarters, 2024-10-01 to 2025-09-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
-23.34x
TTM operating cash flow over long-term debt only, 2022-09-30 (36 months older than the period end)
Return on equity
n/a
average equity is zero or negative
Return on assets
-1,609%
TTM net income over average of 2024-09-30 and 2025-09-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
n/a
capital employed is zero or negative
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$22.6M
market value at close 2026-10-26 on 2025-11-09 shares, plus long-term debt only, 2022-09-30 (36 months older than the period end), minus cash 2022-12-31
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2024-122023-122022-122021-12
Revenue$157.2K$27.6K$0$0
Gross profit$49.0K$11.6K$0n/a
Operating income-$13.4M-$7.3M-$8.7M-$8.6M
Net income-$13.4M-$7.8M-$8.7M-$8.8M
EPS (diluted)-4.23-4.60n/an/a
Operating cash flow-$4.3M-$5.8M-$7.1M-$6.8M
Cashn/an/a$1.8M$8.9M
SEC XBRL, fiscal years, as known on 2026-10-27

ZIVO Stock Sonar score 3/7 axes

Find similar shapesCompare

ZIVO ranks highest on growth (93rd percentile) and risk and compliance (86th), and lowest on financial health (18th), among Pharma & Biotech peers.

Financial health
18
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-23.34x · 18 pct, sector of 371
Growth
93
Inputs
  • Revenue growth, YoY+468.6% · 93 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Risk and compliance
86
Inputs
  • Short interest, % of float+0.5% · 86 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Profitability, Insider conviction, Institutional and government, US patents
  • Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; capital employed is zero or negative; tax provision or pre-tax income not filed for the four quarters
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies